Cancer is characterized by uncontrolled cell growth and the spread of abnormal cells, leading to tumor formation. While genetic mutations are central to cancer initiation, the tumor microenvironment (TME), consisting of immune cells, fibroblasts, blood vessels, and the extracellular matrix, plays a crucial role in supporting tumor progression, metastasis, and therapy resistance. The dynamic interactions between cancer cells and the TME facilitate tumor growth, immune evasion, and resistance to treatment, posing significant challenges in cancer therapy. Emerging strategies targeting the TME, including immunotherapies and anti-angiogenic treatments, have shown promise in disrupting these pro-tumorigenic interactions. Advances in technologies such as CRISPR, organ-on-chip systems, and nanoparticle-based drug delivery provide new opportunities to enhance cancer treatment efficacy. A comprehensive understanding of the reciprocal interactions between cancer cells and the TME is essential for developing effective, personalized therapies that address both the tumor and its supportive ecosystem, thereby overcoming current treatment limitations.